Last updated on Thursday, 27 February 2020

Christus St Vincent Regional Cancer Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2017-01-24NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-12-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401SupportiveOpen Active2016-09-29Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
WFU WF 97115SupportiveOpen Active2018-10-31WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer

Lovelace Medical Center-Saint Joseph Square

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820GI Colorectal PreventionOpen Active2018-07-27SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815GI OtherOpen Active2019-12-27SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST 96144Ill DefinedOpen Active2015-07-28INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-12Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-09SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-09SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400FLung SCLC AdvancedOpen Active2019-11-06SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1616Skin Melanoma AdvancedOpen Active2019-07-02SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Alliance A011401SupportiveOpen Active2016-09-17Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

Lovelace Radiation Oncology

Trial #TypeStudy StatusStatus DateTitle
NSABP B-51Breast AdjuvantOpen Active2017-04-13NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
CCTG MA.39Breast NeoadjuvantOpen Active2018-10-10CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-15ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-02-21NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2017-06-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2017-06-07RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
WFU WF-1801SupportiveOpen Active2019-04-01Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Lovelace Respiratory Research Institute

Trial #TypeStudy StatusStatus DateTitle
LRRI #1054101Lung AncillaryOpen Active2001-03-01LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #TypeStudy StatusStatus DateTitle
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-04-05Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806Breast OtherOpen Active2019-03-14INST LWH 1806: TARGIT New Mexico
INST UNM CR1801Multiple SitesOpen Active2018-09-04INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
Alliance A011401SupportiveOpen Active2017-11-08Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Memorial Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2017-01-26NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807Breast AdvancedOpen Active2020-02-17INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-08-21CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Alliance Foundation Trials AFT-25Breast OtherOpen Active2019-03-27Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2019-07-22NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
SWOG S1815GI OtherOpen Active2019-05-02SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2011-02-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY005GYN OtherOpen Active2019-06-24NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2017-03-27ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
UNM 1709Ill DefinedOpen Active2019-07-02INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-26SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1400FLung SCLC AdvancedOpen Active2019-11-06SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Pharm ML28897/PRO 02Solid Tumors OtherOpen Active2019-07-03Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
Alliance A011401SupportiveOpen Active2016-12-16Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001SupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001ASupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001DSupportiveOpen Active2017-05-24Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship

New Mexico Oncology Hematology Consultants

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-04Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-10-20NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-12-18NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-11-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
Pharm PANC003GI Pancreatic AdvancedOpen Active2019-12-17Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1815GI OtherOpen Active2019-05-13SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance A021602GI OtherOpen Active2019-05-08Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-10-26ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-17Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
UNM 1709Ill DefinedOpen Active2019-07-02INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144Ill DefinedOpen Active2014-12-09INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1400FLung SCLC AdvancedOpen Active2019-11-06SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-17SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-17SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Pharm ML28897/PRO 02Solid Tumors OtherOpen Active2020-02-18Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

NMOHC Gallup

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-18INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Presbyterian Medical Group

Trial #TypeStudy StatusStatus DateTitle
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011502Breast AdjuvantOpen Active2017-05-08Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A171601Breast AdvancedOpen Active2020-01-03Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
SWOG S1815GI OtherOpen Active2019-05-13SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820GI Colorectal PreventionOpen Active2017-11-29SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2020-01-10NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2020-01-14Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144Ill DefinedOpen Active2013-06-04INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm CA209901GU OtherOpen Active2019-06-11Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm PANC003GI Pancreatic AdvancedOpen Active2019-07-22Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-26SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-26SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-04-21Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Alliance A011401SupportiveOpen Active2016-11-01Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Presbyterian Rust Medical Center

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2018-04-19Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-10-02Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A171601Breast AdvancedOpen Active2020-01-03Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1815GI OtherOpen Active2019-04-30SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820GI Colorectal PreventionOpen Active2018-09-14SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2020-01-14NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2020-01-14Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1415CDCCDROpen Active2018-08-20SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144Ill DefinedOpen Active2018-04-10INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm 4010-03-001GYN Endometrial AdvancedOpen Active2020-02-12Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
GOG 0263GYN Cervical AdjuvantOpen Active2018-06-07GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm PANC003GI Pancreatic AdvancedOpen Active2019-07-22Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
SWOG S1900ALung NSCLC AdvancedOpen Active2019-04-05SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-04-05SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-08-04Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A011401SupportiveOpen Active2018-04-19Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
NRG-GY018GYN Endometrial AdvancedOpen Active2020-01-23NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Pharm C-750-01/GOG-3028GYN Cervical AdvancedOpen Active2020-02-13Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
UNM 1419GYN Ovarian AdvancedOpen Active2019-06-04INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
Pharm 3000-02-006GYN Ovarian AdvancedOpen Active2020-02-06Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
NRG Oncology NRG-GY007GYN Ovarian AdvancedOpen Active2018-12-27NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0264GYN Ovarian AdvancedOpen Active2011-04-21GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
NRG Oncology NRG-GY005GYN OtherOpen Active2019-11-06NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Pharm ML28897/PRO 02Solid Tumors OtherOpen Active2019-07-16Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********

UNM - CRTC

Trial #TypeStudy StatusStatus DateTitle
Alliance A011502Breast AdjuvantOpen Active2017-05-03Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG Oncology NRG-BN003Brain OtherOpen Active2017-10-20NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
NCCTG N0577Brain AdvancedOpen Active2017-12-18NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Pharm LNS-101Advanced Solid TumorsOpen Active2019-10-11Linnaeus Therapeutics LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer
Alliance A221505Breast AdvancedOpen Active2018-04-10Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
Alliance A171601Breast AdvancedOpen Active2020-01-03Alliance A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
SWOG S1418/BR006Breast AdjuvantOpen Active2020-01-31SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy andSafety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51Breast AdjuvantOpen Active2016-08-01NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
ECOG-ACRIN EA1131Breast AdjuvantOpen Active2019-01-15ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Pharm RAD1901-308Breast AdvancedOpen Active2019-12-06Radius Pharmaceuticals RAD1901-308: Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
Novartis CBYL719X2402Breast AdvancedOpen Active2017-11-08Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, NoncomparativeStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment
NRG Oncology NRG-BR004Breast AdvancedOpen Active2019-09-24NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807Breast AdvancedOpen Active2019-10-24INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Alliance Foundation Trials AFT-38Breast AdvancedOpen Active2018-03-28Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706Breast NeoadjuvantOpen Active2019-06-24SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG MA.39Breast NeoadjuvantOpen Active2018-09-05CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Pharm WO40181Breast AdvancedOpen Active2018-10-25Genentech WO40181: A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy
Pharm SGNLVA-002Breast AdvancedOpen Active2018-02-20Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Pharm SGNLVA-001Breast AdvancedOpen Active2017-09-26Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer
Alliance A231701CDCCDROpen Active2019-12-11Alliance A231701CD: Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision Making through a Shared Decision Making Intervention
UNM 1525Breast PreventionOpen Active2016-09-22INST UNM 1525: Breast cancer screening among medically underserved women in New Mexico: Comparing outcomes and LOwering recall rates with digital breast tomosynthesis (3D mammography) VErsus full-field digital (2D) mammography. The LOVE New Mexico study)
ECOG-ACRIN EA1151Breast OtherOpen Active2018-08-31ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance Foundation Trials AFT-25Breast OtherOpen Active2018-02-07Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
UNM 1607Breast NeoadjuvantOpen Active2018-04-16INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI)
UNM 1528EpidemiologicalOpen Active2016-04-01INST UNM 1528: Improving Colorectal Cancer Screening Rates in New Mexico Hispanics through Community Partnerships and Implementation Science
INST 1311EpidemiologicalOpen Active2013-02-04INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation
CIBMTR Protocol for a Research DatabaseEpidemiologicalOpen Active2017-06-29CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
WFU WF-30917CDCCDROpen Active2018-10-19WFU WF-30917CD: A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
SWOG S1415CDCCDROpen Active2017-06-07SWOG S1415CD: A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia -(TRACER)
SWOG S0820GI Colorectal PreventionOpen Active2017-10-05SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
INST UNM 1809GI Colorectal PreventionOpen Active2018-12-27INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
NRG Oncology/SWOG NRG-GI004/SWOG-S1610GI Colorectal AdvancedOpen Active2019-07-22NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Alliance A021502GI Colorectal AdjuvantOpen Active2018-10-12Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
UNM TCCPEpidemiologicalOpen Active2017-12-08INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
UNM 1803EpidemiologicalOpen Active2018-06-26INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
INST 1009GI OtherOpen Active2010-11-17INST 1009: The Link Between Chronic Inflammation and Gastrointestinal Cancers (HTR Study)
ECOG-ACRIN EA2165GI OtherOpen Active2019-04-08ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Alliance A021602GI OtherOpen Active2019-05-08Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm XL184-312GI Hepatic AdvancedOpen Active2019-10-31Exelixis XL184-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Pharm 937-00GI Hepatic AdjuvantOpen Active2020-02-04Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Pharm 866-00GU OtherOpen Active2019-11-04Merck 866-00: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
Pharm PANC003GI Pancreatic AdvancedOpen Active2019-06-19Rafael Pharmaceuticals PANC003: A Phase III Randomized Trial of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
UNM 1603GI OtherOpen Active2016-11-30INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
SWOG S1815GI OtherOpen Active2019-04-05SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST Dana-Farber Cancer Institute 18-128GI OtherOpen Active2019-07-15INST Dana-Farber Cancer Institute 18-128: EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options - RCT of Usual Chemotherapy Educational Tools versus Investigational Chemotherapy Educational Tools
Pharm PrTK03GU Prostate AdjuvantOpen Active2017-06-28Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
UNM 1805GU OtherOpen Active2019-01-08INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
Pharm CA209901GU OtherOpen Active2019-06-11Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm 905-00GU OtherOpen Active2020-02-04Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905)
Alliance A031704GU Renal Cell AdvancedOpen Active2019-11-26Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE)
Pharm 1205-201GU Prostate AdvancedOpen Active2018-08-01Constellation Pharmaceuticals 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Pharm 010-00GU Prostate AdvancedOpen Active2020-02-10Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
NRG Oncology NRG-GU005GU Prostate AdvancedOpen Active2018-01-29NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance Foundation Trials AFT-19GU Prostate AdvancedOpen Active2017-12-19Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GY006GYN Cervical AdvancedOpen Active2020-02-18NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-07-23RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-10-20GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
UNM 1509GYN OtherOpen Active2015-12-02INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NRG Oncology NRG-GY005GYN OtherOpen Active2019-06-24NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Pharm 4010-03-001GYN Endometrial AdvancedOpen Active2020-02-12Tesaro 4010-03-001: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
NRG-GY018GYN Endometrial AdvancedOpen Active2019-11-13NRG Oncology NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Pharm C-750-01/GOG-3028GYN Cervical AdvancedOpen Active2019-11-14Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
UNM 1419GYN Ovarian AdvancedOpen Active2018-11-12INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
Pharm 3000-02-006GYN Ovarian AdvancedOpen Active2020-02-06Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
NRG-GY021GYN Ovarian AdvancedOpen Active2020-01-28NRG-GY021: A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
NRG Oncology NRG-GY007GYN Ovarian AdvancedOpen Active2018-12-17NRG Oncology NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0264GYN Ovarian AdvancedOpen Active2011-04-21GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
VBL Therapeutics VB-111-701/GOG 3018GYN Ovarian AdvancedOpen Active2019-08-29VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
INST 1310Head And Neck AdvancedOpen Active2015-02-25INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
ECOG-ACRIN EA3161Head And Neck AdvancedOpen Active2020-02-06ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
ECOG-ACRIN EA3132Head And Neck AdjuvantOpen Active2016-12-14ECOG-ACRIN EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
SWOG S1712Hematology Chronic LeukemiaOpen Active2019-02-21SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Alliance A041702Hematology Chronic LeukemiaOpen Active2019-06-14Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
UNM 1512Hematology Acute LeukemiaOpen Active2018-05-23INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
INST 0551CHematology Acute LeukemiaOpen Active2016-05-02INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
NRG Oncology NRG-HN004Head And Neck AdvancedOpen Active2019-03-20NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
ECOG-ACRIN NHLBI-MDSHematology OtherOpen Active2016-10-06ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
Alliance A061202Hematology MyelomaOpen Active2018-10-03Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
SWOG S1608Hematology Lymphoma Non-HodgkinsOpen Active2019-12-16SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1803Hematology MyelomaOpen Active2019-11-14SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
INST 1306Ill DefinedOpen Active2015-01-01INST 1306: Whole Genome Sequencing of Human Cancer Tissues
Pharm INCB 18424-MA-GD-301Hematology Stem Cell TransplantOpen Active2019-01-29Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
UNM 1709Ill DefinedOpen Active2019-05-30INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609Ill DefinedOpen Active2019-12-10SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG LungMAPLung NSCLC AdvancedOpen Active2019-03-14SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1900ALung NSCLC AdvancedOpen Active2019-03-14SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN E4512Lung NSCLC AdjuvantOpen Active2019-03-01ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216Lung NSCLC AdjuvantOpen Active2016-05-09Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Alliance A081105Lung NSCLC AdjuvantOpen Active2019-11-12Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Alliance A091802Skin Melanoma AdvancedOpen Active2019-12-06Alliance A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
SWOG S1400FLung SCLC AdvancedOpen Active2019-11-06SWOG S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
NRG-LU005Lung SCLC AdjuvantOpen Active2020-02-05NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
NRG Oncology NRG-CC003Lung SCLC AdjuvantOpen Active2019-01-09NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
ECOG-ACRIN EA6134Skin Melanoma AdvancedOpen Active2020-01-03ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-ASolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1801Skin Melanoma AdvancedOpen Active2019-06-27SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
SWOG S1616Skin Melanoma AdvancedOpen Active2019-07-02SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131-LSolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-Z1ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-VSolid Tumors OtherOpen Active2017-07-26ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-ESolid Tumors OtherOpen Active2019-11-15ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-C2Solid Tumors OtherOpen Active2019-03-15ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-TSolid Tumors OtherOpen Active2019-08-26ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-Z1GSolid Tumors OtherOpen Active2019-09-16ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1LSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1KSolid Tumors OtherOpen Active2019-07-29ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Pharm 2455-001Solid Tumors OtherOpen Active2018-03-06Kyowa Kirin Pharmaceutical 2455-001: Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Alliance A011401SupportiveOpen Active2016-10-02Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Pharm SGNS40-001Solid Tumors OtherOpen Active2019-12-18Seattle Genetics SGNS40-001: A Phase I, Open-label Dose Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Alliance Foundation Trials AFT-28SupportiveOpen Active2018-09-12Alliance Foundation Trials AFT-28: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Pharm R3767-ONC-1613Solid Tumors OtherOpen Active2017-12-15Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
Pharm ML28897/PRO 02Solid Tumors OtherOpen Active2019-07-03Genentech ML28897/PRO 02: My Pathway: An Open-Label Phase IIA Study Evaluating Tratuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
DCP-001BSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001CSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001DSupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-001ASupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.***********
DCP-002SupportiveOpen Active2017-11-16NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
INST Johns Hopkins Hospital 1802SupportiveOpen Active2019-09-20INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members
NRG Oncology NRG-CC004SupportiveOpen Active2017-10-12NRG Oncology NRG-CC004: Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
WFU WF 97115SupportiveOpen Active2017-07-06WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
ECOG-ACRIN E1Q11SupportiveOpen Active2018-04-18ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
WFU WF-1801SupportiveOpen Active2019-09-27Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Women's Cancer and Surgical Care

Trial #TypeStudy StatusStatus DateTitle
INST 96144Ill DefinedOpen Active2018-06-13INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives